Oxford Study Identifies Blood Proteins Predicting Prostate Cancer Years Before Diagnosis

OPA WIRE, Oct 27 (OPA) — Oxford University researchers have identified distinct protein signatures in blood plasma that correlate with prostate cancer risk over a decade before symptoms appear. By analyzing samples from more than 2,500 men collected between 1992 and 2000, the team compared 982 participants who later developed the disease against 1,573 who did not. The study measured over 6,000 different proteins to isolate early chemical warning signs.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author. The data revealed that while certain proteins indicate a higher overall risk, others—specifically GZMK and ANXA2—are associated with a lower long-term risk, suggesting a complex immune-system interaction.

Prostate cancer remains the most common cancer among men in the European Union and the second most common globally, trailing only lung cancer. Current data indicates approximately 330,000 new cases are diagnosed annually within the EU, resulting in roughly 75,000 deaths. Distinguishing between slow-growing, non-lethal tumors and aggressive, life-threatening forms remains a primary challenge for clinical oncology.

While the findings represent a significant advancement in understanding the biology of the disease, the researchers emphasized that the protein analysis is not yet a clinical screening test. Further validation is required before these markers can be integrated into standard medical practice. The team aims to utilize these biological pathways to develop targeted preventative strategies for aggressive prostate cancer cases.